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Background: Authors of systematic reviews have difficulty obtaining unpublished data for their reviews. This
project aimed to provide an in-depth description of the experiences of authors in searching for and gaining access
to unpublished data for their systematic reviews, and to give guidance on best practices for identifying, obtaining
and using unpublished data.
Methods: This is a qualitative study analyzing in-depth interviews with authors of systematic reviews who have
published Cochrane reviews or published systematic reviews outside of The Cochrane Library. We included
participants who 1) were the first or senior author of a published systematic review of a drug intervention, 2) had
expertise in conducting systematic reviews, searching for data, and assessing methodological biases, and 3) were
able to participate in an interview in English. We used non-random sampling techniques to identify potential
participants. Eighteen Cochrane authors were contacted and 16 agreed to be interviewed (89% response rate).
Twenty-four non-Cochrane authors were contacted and 16 were interviewed (67% response rate).
Results: Respondents had different understandings of what was meant by unpublished data, including specific
outcomes and methodological details. Contacting study authors was the most common method used to obtain
unpublished data and the value of regulatory agencies as a data source was underappreciated. Using the data
obtained was time consuming and labor intensive. Respondents described the collaboration with other colleagues
and/or students required to organize, manage and use the data in their reviews, generally developing and using
templates, spreadsheets and computer programs for data extraction and analysis. Respondents had a shared belief
that data should be accessible but some had concerns about sharing their own data. Respondents believed that
obtaining unpublished data for reviews has important public health implications. There was widespread support for
government intervention to ensure open access to trial data.
Conclusions: Respondents uniformly agreed that the benefit of identifying unpublished data was worth the effort
and was necessary to identify the true harms and benefits of drugs. Recent actions by government, such as
increased availability of trial data from the European Medicines Agency, may make it easier to acquire critical drug
trial data.
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Selective reporting of data from clinical trials, particu-
larly drug trials, has been well documented [1-3]. Some
trials are not published at all while others are incom-
pletely published, including only those results that are
most positive for the drug being studied. Studies of
selective reporting bias have generally compared the
results of unpublished comprehensive study reports or
trial protocols with published papers. These investiga-
tions have used a variety of sources to identify unpub-
lished studies and outcomes. Researchers have found
that the full reports of drug studies identified by sear-
ching regulatory agency databases have often not been
published, or contain far more data than published
papers [4-6]. Legal actions with drug companies have
identified many unpublished trials or data [7-9]. Investi-
gators have also identified unpublished trials and data by
searching for trial protocols [10,11].
The incomplete or total lack of reporting of drug trials
is so common that our perceptions of the true bene-
fits and harms of drugs are generally much too positive
[5,6,9,12,13]. There have been prominent cases of well
known drugs, such as gabapentin, oseltamivir, and rofe-
coxib where the analysis of unpublished data revealed
important insights about the benefits and harms of those
drugs not previously identified in their initial publica-
tions [14].Therefore, it is critical that systematic reviews
of drugs, which are often used as the basis for clinical
practice guidelines, identify and include unpublished data
from drug trials. The Cochrane Collaboration is a major
producer of rigorous systematic reviews of health care in-
terventions, but only 12% of Cochrane reviews from 2000
to 2006 included unpublished trials [15]. The Cochrane
Handbook for Systematic Reviews of Interventions
suggests identifying unpublished data by contacting
experts, pharmaceutical companies, and national and
international trial registers [16]. No specific guidance for
searching for drug trials is provided and specific sources
of drug trial data such as regulatory agencies or drug com-
pany archives resulting from legal settlements are not
mentioned. In addition, little advice is provided in The
Cochrane Handbook or elsewhere about strategies for
obtaining the data from different sources.
The objective of this project is to provide an in-depth
description of the experiences of researchers doing sys-
tematic reviews in searching for and gaining access to
unpublished data. Additionally, this project aims to give
guidance on best practices for identifying, obtaining, and
using unpublished data from a variety of sources.
Methods
Design
This is a qualitative study analyzing in-depth interviews
with authors of systematic reviews of drugs.Sampling
We interviewed authors of systematic reviews who have
published Cochrane reviews or published systematic re-
views outside of The Cochrane Library. We included
participants who 1) were the first or senior author of a
completed, published systematic review of a drug inter-
vention, 2) had expertise in conducting systematic re-
views and meta-analyses, searching for published and
unpublished data, and assessing methodological biases,
and 3) were able to participate in an interview in English.
The expertise of the participant was confirmed during the
initial contact. We excluded potential participants who
were authors of reviews of devices or interventions other
than drugs.
We used non-random sampling techniques to identify
potential participants who had the knowledge and pro-
fessional experience to address the aims of our study.
We selected systematic review authors who met our in-
clusion criteria with the aim of achieving diversity of re-
search topic area and geographical location. Our sample
size was determined by guidelines from the qualitative
methodology literature that suggests an adequate sample
size for qualitative research should be 20 to 40 people
[17-19]. In a prior cross-sectional, on-line survey [20],
200 Cochrane authors agreed to be interviewed for this
study and 32 met our inclusion criteria. We randomly
selected 18 of these for initial contact; 2 did not respond
after two attempts and 16 agreed to be interviewed (89%
response rate). Fifteen were first authors on one or more
Cochrane reviews, while the sixteenth was a co-author
of several Cochrane reviews (See Figure 1).
The researchers outside of the Cochrane Collaboration
were chosen using non-random and snowball sampling.
Snowball sampling relies on participants in the study or
those with knowledge of the study, to identify other peo-
ple they believe could speak to the questions raised in the
study. The investigators for this project identified authors
of published systematic reviews who met our inclusion
criteria and one researcher who was contacted for the
study referred us to two of his colleagues. In an effort to
geographically diversify this sample, we also sent an e-mail
to colleagues asking for researchers outside of the United
States and Europe who would fit our selection criteria.
Twenty-four non-Cochrane authors were contacted;
four replied that they could not participate, four did not
respond, and 16 were interviewed (67% response rate).
Of the four who could not participate, two were going
to be out of town, one was too busy with professional
commitments, and the fourth did not feel he was quali-
fied to speak to the aims of our study.
Interview procedures
All potential interviewees were contacted up to two























Figure 1 Participant flowchart.
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contacted, potential risks, and procedures for assuring
anonymity. At the beginning of each interview, the par-
ticipant was asked to provide verbal consent and permis-
sion for the interview to be recorded. Our study was
approved by the University of California, San Francisco
Committee on Human Research (# 11–08289).
Of the 32 interviews conducted, one was conducted
in person, while the others were conducted via Skype
(5 face-to-face video, 26 audio only). All interviews were
digitally recorded and uploaded to a secure server acces-
sible by the authors.
Nineteen interviews were transcribed. The cost of
transcription prevented us from transcribing all in-
terviews, so only those that provided unique infor-
mation were transcribed. Extensive notes were taken
from the interviews that were not transcribed, andthose notes were coded in the same way as the trans-
cribed interviews.
The interviews were conducted between June and Sep-
tember 2012.
Interview content
We used a semi-structured interview format to enable
researchers to describe their experiences in their own
words [17,21]. We used an interview guide to ask spe-
cific, yet open-ended questions, which could then be
followed with more probing questions. See Additional
file 1 for interview guide. The interview questions fell
into four main categories:
1. Professional background/history of systematic
reviews or work in this area
2. Understanding what is meant by unpublished data





North America 13 (41)
South America 1 (3)
Europe 12 (38)
Australasia 4 (13)















Graduate research degreeb 16 (50)
aNumbers may add to more than 32 because some respondents had multiple
degrees;bincludes PhD, DrPhil, DrMedSci.
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unpublished data
4. Obtaining and using unpublished data, with a
specific review as an example.
Analytical method
The transcribed interviews and notes were initially co-
ded using an ‘open coding’ scheme that developed itera-
tively from the text. This process helped to identify the
major themes that emerge from the data [17]. The codes
were then assigned to pieces of text to organize the data.
Once the open coding process was complete and the
final set of codes was developed, we systematically coded
the content of all interviews using the iteratively de-
veloped coding scheme. This allowed us to connect
the themes to understand better the interrelationships
among them [17,22]. The interviews were imported
into the qualitative data management software pro-
gram, Atlas.ti, to organize and manage the qualitative
data. We report common themes, as well as areas where
there was variability in responses.
Results
Participant characteristics
As shown in Table 1, the participants were from six
geographical regions in eleven countries. Greater geo-
graphical diversity was achieved among the Cochrane
author sample than the non-Cochrane sample. Of the
32 respondents, 66% (21) had M.D. degrees, six of those
had a joint medical and graduate research degree; 44%
(14) were women.
Major themes
Our study uncovered several major themes. First, study
respondents had different understandings of what was
meant by unpublished data. Second, contacting study
authors was the most common method used to obtain
unpublished data and the value of regulatory agencies as
a data source was underappreciated. Third, using the
data obtained was time consuming and labor inten-
sive, and respondents described a variety of methods
to organize, manage, and use the data in their re-
views. Fourth, respondents had a shared belief that
data should be accessible, but some had concerns about
sharing their own data. Fifth, respondents believed that
obtaining unpublished data for reviews has important
public health implications. Lastly, there was widespread
support for government intervention to ensure open ac-
cess to trial data.
Definition of unpublished data
Most respondents distinguished between entire unpub-
lished studies and data that were missing from published
studies and considered both to be unpublished data.One respondent discussed this saying, ‘the main problem
is that we can’t get access to unpublished studies. We
don’t even know that they exist and for studies we know
about, data are often missing.’Another respondent noted
‘they’re [trials] never published, they’re never made avai-
lable, they’re not out there to inform practice.’
Some respondents felt that unpublished data are
any data not included in a peer reviewed journal article.
Others believed that unpublished meant any data that
were not publically available. Therefore, abstracts, con-
ference proceedings, and other ‘grey literature’ were con-
sidered unpublished. Others disagreed and believed that
abstracts were published data. For these participants, un-
published meant data that could not be publicly ob-
tained in print. One respondent discussed why it is
important to look outside of peer-reviewed journals, ‘we
also want to be aware of what trials are out there and
may be presented at meetings because, you know, jour-
nals may have long publication times, but if you’ve got a
meeting abstract and you can work a little bit with the
author, often you can include some of that data.’
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dents reported that they were missing key pieces of data
to complete their reviews. In this instance, unpublished
data were described as the specific outcomes that were
not included in any publicly available published article
of the drug trial.
Standard deviations were mentioned frequently as ne-
cessary pieces of data that were often missing from pub-
lished reports. One respondent described unpublished
data as being more than outcome data, and included
‘details of the methodology, data that would go in a
Cochrane risk of bias table, and any results not men-
tioned in the report.’
Sources of unpublished data
The respondents’ choices of data sources are shown in
Table 2. Our analysis of the interview data suggests that
these choices were influenced by how they defined un-
published data and whether they believed a source had
the data and would be willing to share them. The most
frequently mentioned source of unpublished data was
study authors. All respondents contacted study authors,
yet many did not go further because they did not know
that the data might be available elsewhere or they did
not believe they would be able to gain access to the data.Table 2 Advantages and disadvantages of sources of unpubli
Sources of unpublished data Advantages
Study authors They have the data
Drug companies • Have complete clinical study r
Regulatory agencies • Includes summary data from c
Grey literature Provide information about studi
published, for example, presente
Law firms - class action suits in the US • Can uncover all of the data fo
Grant organizations • Provide a list of all studies the
Marketing materials from companies
and financial reviews
• More or different data may ap
publications compared to the
The media – journalists, press officers • Companies will respond to m
Clinical trial registries • Provide awareness of all of th
conducted on a certain drugSome respondents turned to trial registries to help
identify entire unpublished trials. The benefit of the trial
registry is that it can help a researcher identify trials for
which no outcomes have been reported. The shortco-
mings are that they do not provide any data and there is
no contact person listed.
Others sources that were less frequently mentioned
were grey literature, which, depending on the respon-
dent, might include non peer-reviewed publications, ab-
stracts, conference proceedings, or dissertations. One
respondent mentioned law firms involved in class action
lawsuits as a data source, but noted that while a class ac-
tion lawsuit can reveal all of the trial data, they do not
occur very often and cannot be considered a source for
many drugs. The media, press releases, and grant organi-
zations were also mentioned as potential sources for un-
published data.
Strategies for obtaining the data
Contacting the study author
Respondents used similar processes to approach study
authors about obtaining unpublished data and believed
two methods were most successful. The first was keeping
the initial e-mail to the study author descriptive, friendly,
and concise. Making it easy on the study authors wasshed data described by interview respondents
Disadvantages
• Not always responsive
• Want to keep the data to themselves for
their own publications
eports • Rarely responsive
• Want to know what you want to do with
the data
linical trials • Not a user friendly interface
• People do not know what information/data
are available on the agencies websites
• Not as much information about older drugs
• Data on phase 4 studies often missing
es that may be
d at conferences.
• Does not provide key pieces of outcome data
• Rarely peer reviewed
r a given drug • Happens for few drugs
• Tens of thousands of pages of documents
to search
• Judges must agree to release the data
y sponsor • Sponsor a small number of studies
pear in financial
scientific literature
• Can suggest that unpublished data exist, but
the data must still be obtained
edia pressure • Data may not be complete
e trials being
in a certain area
• Results data are generally not available
• Some registries do not contain registration
of Phase 1 or 4 trials
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ent stated, ‘it’s just a matter of understanding that people,
even if they want to collaborate, they don’t have a lot of
time to do that. So, if you make their life more compli-
cated, they’ll say, “Okay, why do I need this problem?”’
The second method that increased response rates was to
try to establish a personal connection with the author.
Additionally, respondents noted that more senior authors
were more likely to be successful in obtaining data. Re-
spondents believed they would also have more success if
their request came from a larger organization with which
the researcher was affiliated (for example, a Cochrane
Center or the World Health Organization) rather than
contacting the author as ‘a lone wolf.’ Generally, respon-
dents would only contact a study author twice if they
received no response. However, others believed that per-
sistence was important. One respondent contacted unre-
sponsive study authors ‘every six months for two to three
years, until the review was completed.’
Unresponsiveness or refusal to share data
There were three main reasons provided to our respon-
dents as to why the study author(s) they contacted
would not or did not provide the data our respondents
were seeking. The first was that the study author had
moved from one institution to another and no longer
had access to the data. The second reason was that the
study author did not have the resources to search for or
gather the data. Two respondents discussed the need to
obtain extra funding to get unpublished data. One paid
study authors directly for the data, which he stated in-
creased the response rate considerably.
The third reason noted by our respondents was that
authors wanted to maintain control over the data for
their own publications and professional advancement.
One respondent described it this way, ‘clinical trialists
are quite willing to share their data if they had published
their own results.’ Although respondents did not agree
with this practice, as academicians, they shared similar
concerns. One respondent stated, ‘I could understand if
you put a lot of energy and resources into gathering data
that you don’t want to just turn it over to someone else
to publish all of your papers with.’
Pharmaceutical companies
Researchers who were unable to obtain the data from
the study author believed that the potentially most fruit-
ful next step would be to contact the pharmaceutical
company that sponsored the trial. However, due to past
negative experiences or perception, many respondents
did not believe they would be granted access to the data
and concluded that the attempt would not be worth the
effort. While Cochrane authors were less likely to con-
tact drug companies, there was a general distrust of thepharmaceutical industry by all respondents. One res-
pondent stated, ‘an overture to a pharmaceutical com-
pany to get data from them is not likely to meet with
any kind of success. You would have to – I would as-
sume that anything I got back from them was not likely
to be valid or that you couldn’t actually depend on it.’
Drug companies often responded with reasons as to why
the data could not be released. One respondent stated
that she was told by multiple company representatives
that the ‘quality of the studies is just too poor to do
meaningful analysis and based on that argument we did
not get the data.’ Even when companies were required
through legal action to make data available, most re-
spondents believed it would be difficult to make the ana-
lysis free of industry influence since some settlements
required that company employees still be involved as
consultants.
One of the most informative and comprehensive docu-
ments that a reviewer can obtain from the pharmaceu-
tical company is the clinical study report. The ‘clinical
study reports contain hundreds to several thousand pa-
ges and at an aggregate level contain everything.’ How-
ever, the immense size of the reports makes the process
of finding the needed data very laborious and time con-
suming. The size also allows unflattering data to be hid-
den among the thousands of pages. One respondent
discussed how he had ‘no doubt’ that the large size of
the clinical study report was a ‘deliberate tactic that drug
companies use that they drown us with data. They sub-
mit so many thousands of pages on their clinical trials
that no one in the whole world will ever read all this.
And there are examples that they have hidden, even
deaths, deeply inside a report. And there is not any big
chance that anybody will ever find it.’
Despite the size of clinical study reports, one respon-
dent described them as ‘formulaic’ and said that if one
understands the formula, then one can easily navigate
through the documents. For example, a respondent sta-
ted, ‘once you’ve got your head around the structure of
one clinical trial report from a company, and a drug,
and topic then by in large you know your way around
most of the others…sometime it’ll be as simple as table
twenty one is always telling you about death… almost all
of them have got extensive indices at the front and/or
back… almost all of them as well have very extensive
sections dealing with the methodology, how missing data
were dealt with and so on. And when it comes to signifi-
cant and severe adverse events they’ll usually have indi-
vidual patient narratives tucked away in the appendices
and one can look and search for those as well.’
Another respondent conceded that these reports are
helpful, and ‘your means of verification with the clinical
study reports are far higher’ than in a peer-reviewed
journal article. He did however, feel that ‘the clinical
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to the regulators, so you shouldn’t be trusting it.’
Some respondents believed that if you didn’t work
with companies you would be cut off from obtaining
data. Respondents who had success with drug companies
had usually been involved in a review supported by a
drug company that agreed to make data available. But
even those who had been involved in a review with a co-
operating drug company may not have success obtaining
data for another review.
While most of our respondents worked in academia,
one who currently works for a pharmaceutical company
had a different perspective: ‘the pharmaceutical compan-
ies in general do allow access to the data, but not for
anyone. So, typically what would happen is there would
be a protocol, it would be reviewed by an internal
committee, and there would be an assessment of the
scientific rigor of the work, and the capability of the
investigator. To provide someone with data requires a
fair bit of work. And, so there would be an assess-
ment of is there a good trade off for the amount of
work required to provide the data and the expected
utility of the data once completed.’
Regulatory agencies
Respondents were generally unaware of data from re-
gulatory agencies. The Food and Drug Administration
(FDA) and the European Medicines Agency (EMA) were
the two regulatory agencies mentioned by respondents.
Reviewers saw the FDA as a particularly valuable re-
source because the FDA has data and analyses that do
not get published in peer-reviewed journals. One re-
spondent outside of the United States had high praise
for the FDA, stating, ‘the FDA is brilliant in the last few
years because of what it does and the way it treats data…
What happens now is that the FDA will perform its own
analyses on the company’s data, they won’t just rely any-
more on the company’s analyses of data and that analysis
includes an analysis of the individual patient level and it
includes an analysis, which we think is more appropriate
where they use a variety of different techniques for dea-
ling with data when patients drop out of studies.’
Since the regulatory agency has the documentation
necessary for approval, one respondent believed that
‘having access to regulatory agency submissions is really
the kind of gold standard of information on results be-
cause it’s the full report of all the analyses that have been
done and it’s the full protocol that’s available through
those submissions.’ However, respondents noted a num-
ber of major limitations of the data available from the
FDA website: ‘a lot of it is redacted for proprietary rea-
sons, and it’s not necessarily posted in the most timely
fashion or in the most convenient format.’ In addition,
the FDA website does not include raw data, completedata on harms, or all post-approval studies. Individual case
report forms are not readily available, although summaries
of these case reports are provided by the FDA.
The FDA’s site is not user friendly. One respondent
found ‘it very hard when I go to the FDA site to find re-
ports. I really have to seemingly dig around a long time,
and I suspect a lot of people don’t even bother.’ One re-
spondent felt that the site was so difficult to navigate,
and the format of the data so unwieldy, that she pre-
ferred not to use it as a source of data. One reviewer
who acknowledged that searching the FDA site is ‘a
daunting task’ noted that experience made it easier and
that reviewers could be trained to use the site efficiently.
One respondent was optimistic about the direction the
regulatory agencies were heading with regard to making
data more available. He said, ‘they have become more
accepting of the fact that it’s really illogical and unfair
that they should have access to all the information and
then to approve the drug or device, and then those of us
who actually use or prescribe those interventions then
only have access to a biased subset of that information.’
Using the data in reviews
Respondents discussed the processes they used to or-
ganize and manage the data that they obtained. One
respondent discussed the collaboration required after re-
ceiving data from a drug company that were a ‘complete
mess. I had no idea what was going on. Fortunately, it
being [Academic institution], a few very clever people
around, one of whom was an Associate who was an ab-
solute whiz kid at spread sheets and artificial intelligence
and he had mechanisms which allowed us to make sense
of the data.’ Another respondent described the process
of cleaning the data for use in the review as ‘a huge
project. I have had two full-time researchers working on
this for a full year now. So we are trying to develop the
methods whereby we can digest these thousands of
pages without as I told you having to read every word
in them.’
The process for extracting usable data can span
months or years. One respondent described the pro-
cess with his research team whereby three of them
‘sat in my room with, I think, three or four com-
puters, all big screens running simultaneously, looking
through the data - checking and double checking,
triple checking each other and entering data into our
Pro forma sheets at the same time. So we just got it
done while we were all concentrating on it.’ Another
respondent, working under a deadline, had received
all of the data, and then checked ‘data for 53 studies,
14,000 patients, then every study was checked by a
statistician, I mean the complete IPD (individual patient
data) data…we were working night and day, night and
day because that was a special project.’
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too much. One respondent was told he could receive 70
meters of paper from a regulatory agency and ‘gave up.’
Another respondent who had to manually go through
paperwork felt that it was ultimately ‘not worth doing
that. It was a good three days work for a table of data.’
The respondents felt that it was important to be discern-
ing about time spent gathering certain data and weigh
that against how critical those data are for that review.
Beliefs about unpublished data
The respondents expressed a variety of views on collabor-
ation and willingness to share data with other researchers,
language barriers, the role of systematic reviews and their
impact on public health, and ideas about how the accessi-
bility of data can be increased.
Collaboration
Most of the respondents would share data with other
researchers when asked and believed that data should
be available. However, some respondents who were also
trialists were unwilling to share their own data or colla-
borate with other trialists. One respondent thought the
main barrier to data sharing was a lack of collaboration
among researchers, and he found it ‘singularly unhelpful
to work with people outside [of his institution].’ Others
felt ‘uncomfortable’ about sharing data because data
could be misrepresented or inappropriately analyzed post
hoc. While some believed that data should be available,
they felt that the availability should be limited to quali-
fied researchers who could demonstrate how the data
would be used. Others felt that unpublished data should
be widely available to the public with one suggesting that
The Cochrane Collaboration establish a database of all
unpublished data collected for Cochrane Reviews.
Language issues
Language was viewed as a barrier. One respondent said
that ‘for better or for worse, English probably is the
common currency in terms of scientific publication, and,
so most of the best scientists want their work published
in English.’ Therefore, non-English language speakers
are at a disadvantage when it comes to obtaining data
from English-language publications.
There were differing opinions as to how the inclusion
of non-English publications would affect the outcome of
reviews. Some respondents did not think it was worth
the effort to obtain data published in languages other
than English, while others felt that it was important not
to exclude those studies.
Public health
All of the respondents believed that their efforts to ob-
tain unpublished data were important. Many respondentsagreed that drug trial data should be more easily access-
ible to the public. One respondent stated that, ‘we should
have the totality of the information available to us and if
there are studies which have been done and they are rea-
sonable studies, which could help make decisions either
about the effectiveness or harms of medicines then they
damn well ought to be in the public domain ‘cause it’s the
public that are taking the tablets.’Another respondent also
believed these data should be public, and said ‘This idea
that they contain material that the company should
be able to keep private is absurd. Human lives were
involved in these trials and I think that information
should be public.’Another respondent noted that
‘patients would be shocked’ to know that data were
unavailable to researchers.
Others stated that without access to unpublished data,
the true harms and benefits of many drugs would never
be known. Respondents noted that conclusions of drug
reviews that do not include unpublished data are
‘dangerous,’ with one noting, ‘peer review journal articles
represent a cherry-picked subset of what went on. And I
think clinicians and researchers need to know the whole
story and not just this sanitized cherry-picked version of
the truth.’ One respondent felt that The Cochrane
Collaboration was impeding progress by publishing re-
views that do not have the full data on a drug, noting
‘we don’t expect Cochrane reviews to be biased towards
a certain product, but they are.’ He suggested that
Cochrane reviews should ‘come to the conclusion that
they can’t get the data’ rather than a conclusion about
the efficacy of a drug.
Some of the respondents described how their reviews
changed prescribing practices after they exposed harms
by including unpublished data. One respondent’s review
caused the drug company to remove the drug from the
market and cease all ongoing clinical trials. Some res-
pondents felt that difficulty in obtaining data caused
unacceptable delays of public health significance. One
researcher who was finally able to obtain data from the
FDA after three years of repeated Freedom of Informa-
tion (FOIA) requests stated simply, ‘I think my review is
ten years too late.’ The results of his review demons-
trated harm at the high dose of the drug. Another re-
spondent who has been a vocal critic of industry felt
that his work had negatively impacted public health and
believed, ‘I’ve probably increased the sales of drugs.
Companies can use critics to increase sales of their drugs.
I don’t think I’ve made any difference or whatever, maybe
made things worse’.
Ways to increase data access
All of the respondents believed that trial data should be
made available and that access should be increased but
there were differing opinions as to the best way to make
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ment intervention and regulation. One respondent de-
scribed how government intervention could help, ‘it’s
very easy if you want to, to demand as a condition for
having approval of doing the trial, you need to provide
all the data within a certain amount of time… And if
you don’t provide the totality of the data, then there
could be sanctions like if it is a drug company, the sanc-
tion could be that they are not allowed to do anymore
trials.’ Another respondent concurred that it ‘would be a
great thing for the government to manage and make ac-
cessible.’ One US respondent felt that political will could
facilitate access to data and found it necessary to ‘get a
Senator or Congressman to get it for you.’
There were differing opinions, though, as to who could
access the data. Some felt that it should be publicly
available to anyone without any barriers. Others felt that
the process should be more discerning, with data avai-
lable to scientists and researchers who could understand
and make sense of the data as well as demonstrate how
they would use the data, which could involve submitting
a protocol for the review.
Discussion
Researchers with experience searching for unpublished
drug trial data uniformly agreed that finding unpub-
lished data has important public health consequences in
terms of identifying the true harms and benefits of drugs
and improving the reliability of systematic reviews
[5,6,12,13]. They also recognized that obtaining the data
takes time and effort that could delay the public health
impact. The respondents felt that reviews that were de-
pendent on data from drug company sponsored trials
and did not contain unpublished data could not reach
accurate conclusions but at the same time they distrusted
drug companies as a source of data. Our respondents
identified several challenges to obtaining unpublished
data, including nonresponsive study authors, language dif-
ficulties, and unawareness of data from drug regulatory
authorities. After unpublished data were indentified, our
respondents found that considerable effort was needed to
get the data into a format that could be used in the re-
views. Not only does the numerical data need to be avail-
able, but reviewers must have sufficient information about
the characteristics of the studies with unpublished data in
order to be able to assess the risks of bias of these studies.
Our study has limitations associated with qualitative
interview studies. Although our purposive sample se-
lected researchers who had experience with searching
for unpublished data who worked in a variety of topic
and geographical areas, our findings may not be gene-
ralizable to all authors of systematic reviews. However,
the suggestions given by our respondents can be used
and tested by systematic review authors without a negativeimpact to their review. In fact, the lessons learned through
this project can serve to strengthen and improve the
process for conducting systematic reviews. Our high re-
sponse rate and openness of the interviewees suggests a
willingness to address the topic of searching for unpub-
lished drug trial data and a desire to change the current
paradigm.
Researchers, particularly Cochrane authors, have tradi-
tionally contacted study authors to obtain missing data.
However, the difficulties experienced by our interviewees
suggest a need for greater accountability. Trial data that
are maintained in accessible databases or study reports
should be available long after authors are out of contact
via institutional mechanisms for data sharing [23].
A paradoxical finding of our study is that while all res-
pondents demanded access to unpublished data for their
reviews, some expressed unwillingness to share their
own trial data. Researchers are concerned that their own
data will be misinterpreted or analyzed inappropriately.
However, if the data are made freely available and the
analyses are transparent, it will be possible to debate any
conflicting findings in an open scientific discourse. Thus,
not only should data be accessible but their analysis
should also be transparent. Given the competitive climate
in research, publication, and fundraising, researchers who
voluntarily share their data when such sharing is not re-
quired for everyone may be at a disadvantage. Therefore,
standards for data sharing should be uniform and univer-
sally applied.
Respondents who had obtained data from regulatory
agencies found the experience to be well worth the ef-
fort. However, data from a recent quantitative survey
suggests that drug regulatory authorities are underuti-
lized as a source of drug trial data [20]. Access to data
from regulatory authorities could be improved by stand-
ardizing the reporting of data, including more data on
harms, and including individual patient data. While most
of our respondents had experience with obtaining data
from the US FDA, the EMA may become a more val-
uable data source in the future. In 2010, the Nordic
Cochrane Centre obtained a break-through at the EMA
after having complained to the European ombudsman
that the agency refused to provide protocols and clinical
study reports to the Centre [24]. This created an import-
ant precedent, as everyone can now obtain such access
in accordance with the principles on which the EU is
founded. Other drug agencies should follow suit, as the
traditional secrecy is not in the patients’ interest and
cannot be defended ethically [25].
Difficulties were often encountered when attempts
were made to obtain data from drug companies. Respon-
dents with prior experience working with drug companies
were more likely to obtain data but even they stressed that
users of the data must be aware that industry controls the
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pendent analyses should be available. Difficulty in
obtaining data from drug companies could be avoided by
enforcing legal requirements to provide the data.
The Cochrane Handbook for Systematic Reviews of
Interventions [16] suggests identifying unpublished data
by contacting experts, pharmaceutical companies, national
and international trial registers (for example, clinicaltrials.
gov), and other specific trial registers. No specific guid-
ance for searching for drug trials is provided and sources
of drug trial data, such as legal settlements, regulatory
agencies, human subject approvals, and annual reports of
funding agencies are not mentioned. In addition, little ad-
vice is provided in The Cochrane Handbook or elsewhere
about strategies for obtaining the data from different
data sources. Future revisions of the Cochrane
Handbook should take into account reviewers’ experi-
ence with obtaining unpublished drug study data from
regulatory agencies.
Conclusion
Our findings suggest that the burden of responsibility
for making clinical drug trial data available to resear-
chers should not lie with individual study authors or with
sponsoring companies, but with government authorities.
Some respondents suggested advocacy approaches such as
doctors refusing to prescribe drugs or patients refusing to
enroll in clinical trials until all the data become available.
However, drug trial research is an international activity
and these advocacy efforts would be difficult to implement
globally. Others felt that change needed to be made at the
highest levels, whereby large entities such as the World
Health Organization, national health departments, state
agencies, and even large managed care organizations
could require full availability of data for inclusion of
drugs in their formularies. Government intervention
could take the form of enforcing requirements to make all
data available in clinical trial registries, granting ethics ap-
proval for trials only when data from previous trials have
been published, and making all data from drug regulatory
authorities available. Some of this is not far away. At a
workshop at the EMA on 22 November 2012, EMA an-
nounced that it will in future ask the companies to submit
not only the study protocols and the clinical study reports
but also the raw anonymized patient data in a statis-
tically useful format, which it will make available to
the public [26].
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